Innovative Leukemia and Lymphoma Therapy provides a complete and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma that are being introduced in the clinic today. Written by international experts in the field, this volume examines clinical studies on topics such as:tyrosine kinase inhibitors, histon deacetyla

chapter 1|21 pages

Gene Expression Profiling to Detect New Treatment Targets in Leukemia and Lymphoma: A Future Perspective

ByTorsten Haferlach, Wolfgang Kern, Alexander Kohlmann

chapter 2|21 pages

Individualized Tumor Response Testing in Leukemia and Lymphoma

ByAndrew G. Bosanquet, Peter Nygren, Larry M. Weisenthal

chapter 3|40 pages

Minimal Residual Disease

ByJacques J. M. van Dongen, Tomasz Szczepański, Vincent H. J. van der Velden

chapter 4|13 pages

New Methods for Clinical Trials: AML as an Example

ByElihu Estey

chapter 5|26 pages

Monoclonal Antibody Mediated Treatment in Acute Myeloid Leukemia

ByCh. Michel Zwaan, Marry M. van den Heuvel-Eibrink

chapter 7|35 pages

Radioimmunotherapy of Hematological Malignancies

ByTim Illidge, James Hainsworth

chapter 8|21 pages

Differentiation Induction in Acute Promyelocytic Leukemia

ByAdi Gidron, Martin S. Tallman

chapter 9|25 pages

DNA Methylation and Epigenetics: New Developments in Biology and Treatment

ByJesus Duque, Michael Lübbert, Mark Kirschbaum

chapter 10|23 pages

The Emerging Role of Histone Deacetylase Inhibitors in the Treatment of Lymphoma

ByMatko Kalac, Owen A. O’Connor

chapter 11|25 pages

Antileukemic Treatment Targeted at Apoptosis Regulators

BySimone Fulda, Klaus-Michael Debatin

chapter 12|27 pages

Angiogenesis in Hematological Malignancies

ByAlida C. Weidenaar, Hendrik J. M. de Jonge, Arja ter Elst, Evelina S. J. M. de Bont

chapter 14|23 pages

Active Specific Immunization by the Use of Leukemic Dendritic Cell Vaccines

ByIlse Houtenbos, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht

chapter 15|25 pages

CDK Inhibitors in Leukemia and Lymphoma

ByYun Dai, Steven Grant

chapter 16|32 pages

FLT3: A Receptor Tyrosine Kinase Target in Adult and Pediatric AML

ByMark Levis, Patrick Brown, Donald Small

chapter 17|18 pages

Treatment of Chronic Myeloid Leukemia with Bcr-Abl Kinase Inhibitors

ByMichael J. Mauro, Michael C. Heinrich

chapter 18|19 pages

Tyrosine Kinase Inhibitors: Targets Other Than FLT3, BCR-ABL, and c-KIT

BySuzanne R. Hayman, Judith E. Karp

chapter 19|20 pages

Tyrosine Phosphatases as New Treatment Targets in Acute Myeloid Leukemia

ByI. Hubeek, K. Hoorweg, J. Cloos, Gertjan J. L. Kaspers

chapter 20|21 pages

Proteasome and Protease Inhibitors

ByN. E. Franke, J. Vink, J. Cloos, Gertjan J. L. Kaspers

chapter 22|12 pages

Targeting Notch Pathways

ByJennifer O’Neil, A. Thomas Look

chapter 23|14 pages

mTOR Targeting Agents for the Treatment of Lymphoma and Leukemia

ByAndrea E. Wahner Hendrickson, Thomas E. Witzig, Scott H. Kaufmann

chapter 24|23 pages

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning

ByFrédéric Baron, Frederick R. Appelbaum, Brenda M. Sandmaier